Application of oat beta-glucan in preparation of fat-reducing product
By using oat β-glucan as the active ingredient of fat-reducing products, obesity, liver damage, elevated blood lipids and intestinal flora disorders caused by high-fat diets, significantly improving liver function and bile acid metabolism, and providing Effective health interventions.
Patent Information
- Application Number
- CN202411371463.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-12-06
AI Technical Summary
A high-fat diet leads to obesity, liver damage, elevated blood lipid levels, intestinal flora disorders and bile acid metabolism abnormalities, and the existing technology is difficult to effectively solve these health problems.
Using oat β-glucan as the active ingredient of fat-reducing products, it uses multiomic analysis and biochemical evaluation of intestinal microbiota and bile acids to study its lipid-reducing mechanism of high-fat diets, and provides intervention measures to reduce Effects of high-fat diet.
Oat β-glucan can reduce weight gain, improve liver function, reduce liver fat accumulation, restore intestinal flora diversity, regulate bile acid metabolism, and significantly improve health problems induced by high-fat diets.
Smart Images

Figure CN119073596A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of health care products, and in particular relates to the application of oat beta-glucan in the preparation of fat-reducing products. Background Art
[0002] Oat bran is derived from oats, an annual herbaceous plant of the Poaceae family, and is a valuable source of minerals, vitamins, and cell wall polysaccharides such as cellulose, arabinose, and β-glucan. Oat β-glucan (BG) is a non-starch polysaccharide that is mainly found in the aleurone and subaleurone layers of oat grains. It is characterized by a unique linear helical structure formed by β-1,4-glucoside and β-1,3-glucoside bonds. BG has a variety of physiological activities, including anti-diabetic, cholesterol-lowering, immune-enhancing, and anti-cancer properties, and has a significant effect on lowering blood sugar and cholesterol.
[0003] Consumption of a high-fat diet rich in saturated fat and cholesterol can lead to health problems such as obesity, metabolic syndrome, and chronic inflammation. Long-term intake of a high-fat diet is closely associated with increased levels of total cholesterol (TC), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) in the serum and liver of animals. The interaction between diet, health, and the gut microbiota has attracted significant research attention. The gut microbiota is highly sensitive to changes in food intake and the physiological state of the digestive system, and the intake of a high-fat diet significantly reduces the diversity of the gut microbiota. Bile acids play a vital role in lipid absorption and act as hormone-like regulators of energy expenditure, inflammation, lipid and carbohydrate metabolism in the liver and other peripheral organs. Studies have shown that a high-fat diet has an adverse effect on the composition and function of intestinal microorganisms, leading to an imbalance in the gut microbiota, intestinal inflammation, and altered intestinal barrier function. In addition, a high-fat diet can also have an adverse effect on bile acid metabolism. Summary of the invention
[0004] The present invention provides an application of oat β-glucan in the preparation of a fat-reducing product, wherein the application is any one of the following:
[0005] (1) Reduce weight gain caused by a high-fat diet;
[0006] (2) Improve liver damage and elevated blood lipid levels induced by a high-fat diet;
[0007] (3) Reduce liver fat accumulation induced by a high-fat diet;
[0008] (4) Improve intestinal flora disorders induced by high-fat diet;
[0009] (5) Regulate abnormal bile acid metabolism caused by a high-fat diet.
[0010] Preferably, oat β-glucan is the only active ingredient in the fat reduction product.
[0011] More preferably, the fat-reducing product is a health product.
[0012] More preferably, the fat-reducing product is in the form of tablets, powders, capsules, tea bags, water pills or oral liquids.
[0013] The present invention also provides a fat-reducing product, wherein the fat-reducing product contains oat beta-glucan.
[0014] Preferably, oat β-glucan is the only active ingredient in the fat reduction product.
[0015] More preferably, the fat-reducing product is a health product.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] This study mainly studies the effects of BG on HFD-fed mice by combining multi-omics analysis of gut microbiota and bile acids with biochemical assessments to elucidate the lipid-lowering mechanism of BG in regulating HFD-induced obesity. The results of this study provide new insights into oat beta-glucan as an intervention to mitigate the effects of HFD intake. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 The weight changes and food intake of each group of mice in Example 1, wherein A is a graph showing the weight changes of mice; and B is a statistical graph showing the food intake of mice.
[0019] Figure 2 The results of the effects of BG on liver dysfunction and lipid metabolism in HFD-induced obese mice in Example 1, where A, plasma ALT level; B, plasma AST level; C, plasma TG level; D, plasma TC level; E, plasma LDL-C level; F, plasma HDL-C level. Data are expressed as mean ± SEM, and one-way ANOVA was used for statistically significant differences. ** indicates a significant difference compared with the NOR group (P < 0.01), and ## indicates a significant difference compared with the HFD group P (P < 0.01).
[0020] Figure 3 The fat accumulation in the liver of each group of mice in Example 1. Representative images of liver histopathology (H&E) 200×.
[0021] Figure 4 The colon inflammatory response of each group of mice in Example 1. Representative images of colon histopathology (H&E) 200×.
[0022] Figure 5The intestinal flora structure of each group of mice in Example 1, including A, Shannon index analysis; B, Chao1 index; C, Simpson index; D, ACE index analysis; E, PCA analysis; F, PCoA analysis. Data are expressed as mean ± SEM, and one-way ANOVA was used for statistically significant differences. ** indicates a significant difference compared with the NOR group (P < 0.01), and ## indicates a significant difference compared with the HFD group P (P < 0.01).
[0023] Figure 6 The abundance of intestinal flora of each group of mice in Example 1, including A, the abundance of Firmicutes at the phylum level; B, the abundance of Bacteroidetes at the phylum level; C, the abundance of Firmicutes / Bacteroidetes at the phylum level; D, the intestinal microbial composition of each group at the phylum level; E, the intestinal microbial composition of each group at the genus level. Data are expressed as mean ± SEM, and statistically significant differences were analyzed by one-way ANOVA. ** indicates a significant difference compared with the NOR group (P < 0.01), and ## indicates a significant difference compared with the HFD group P (P < 0.01).
[0024] Figure 7 These are the LEfSE analysis results between different groups in Example 1.
[0025] Figure 8 The figure shows the changes in the bile acid pool of each group of mice in Example 1, wherein A, bile acid heat map between NOR group and HFD group; B, PCA map of bile acid between NOR group and HFD group; C, differential bile acid substances between NOR group and HFD group; D, bile acid heat map between HFD group and BG-L group; E, PCA map of bile acid between NOR group and BG-L group; F, differential bile acid substances between HFD group and BG-L group; G, bile acid heat map between HFD group and BG-M group; H, PCA map of bile acid between HFD group and BG-M group; I, differential bile acid substances between HFD group and BG-M group; J, bile acid heat map between HFD group and BG-H group; K, PCA map of bile acid between HFD group and BG-H group; L, differential bile acid substances between HFD group and BG-H group. DETAILED DESCRIPTION
[0026] The β-glucan used in the following examples was purchased from Zhejiang Shenyou Biotechnology Co., Ltd.
[0027] Example 1
[0028] 1.1 Dosage regimen
[0029] After 1 week of adaptation, 6-week-old male C57BL / 6J mice were randomly divided into 6 groups, 8 mice in each group, and fed for 12 weeks: NOR group was fed with normal diet for 1-12 weeks, HFD group was given high-fat diet for 1-12 weeks, Orilistat group was given high-fat diet for 1-12 weeks, and Orlistat was given from the 8th week, BG-L group, BG-M group, BG-h group were given high-fat diet for 1-12 weeks, BG-L group was given 200 mg / kg / day BG for 1-12 weeks, BG-M group was given 400 mg / kg / day BG for 1-12 weeks, BG-h group was given 800 mg / kg / day BG for 1-12 weeks, and oat β-glucan was administered by gavage. The water intake and food intake of mice were monitored daily, and the body weight of mice was recorded twice a week.
[0030] 1.2 Plasma biochemical indicators
[0031] Blood indicators reflecting liver function, such as plasma aspartate aminotransferase (AST), alanine aminotransferase (ALT), triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C), were detected using corresponding kits.
[0032] 1.3 Histopathological examination of liver and colon
[0033] Fresh liver and colon specimens were fixed with 4% paraformaldehyde. After wax wrapping, the samples were cut according to standard protocols. The tissue sections were observed under a microscope and photographed using hematoxylin & eosin (H&E) staining.
[0034] 1.4 Fecal DNA extraction and high-throughput sequencing analysis
[0035] Genomic DNA from stool samples was purified using the Zimo Research BIOMICS DNA Microprep Kit (No. D4301). Sequencing and bioinformatics analysis were performed by Genesky Biotechnology (Chengdu, China). The variable region of the 16S rRNA V4 gene was PCR amplified according to the primer sequences designed in the literature. After library construction using the Illumina Truseq DNA PCR-Free Sample Prep kit (FC-121-3001 / 3003), high-throughput sequencing was performed using the Illumina Hiseq Rapid SBSkit v2 (FC-402-4023500Cycle) kit. Alpha diversity analysis, beta analysis, analysis of differences in diversity and community structure, and species-level correlation analysis were performed using QILME, Mothur, and R software.
[0036] 1.5 Analysis of bile acid types and contents
[0037] After adding 400 μL of extraction solvent (acetonitrile-methanol, 1:1, precooled at −40 °C), 100 μL of plasma samples were vortexed for 30 s, sonicated in an ice-water bath for 10 min, incubated at −40 °C for 1 h, centrifuged at 12000 rpm (Rcf = 13800 (× g), R = 8.6 cm) and 4 °C for 15 min, and the clear supernatant was transferred to an autosampler vial for UPLC-MS / MS analysis.
[0038] UPLC separation was performed using a UPLC system (vanquish, Thermo fisher scientific) equipped with an acquityUPLC BEH C18 column (150*2.1mm, 1.7μm, waters). Mobile phase A was 5mmol / L ammonium acetate aqueous solution, and mobile phase B was acetonitrile. The column temperature was set to 45°C. The autosampler temperature was 4°C, and the injection volume was 1μL. Bile acids were determined using an Orbitrap Exploris120 mass spectrometer (Thermo fisher scientific). Typical ion source parameters were set as follows: spray voltage: +3500 / -3200V, sheath gas (N 2 ) Flow rate: 40mL / min, auxiliary gas (N 2 ) Flow rate: 15mL / min, auxiliary gas (N 2 ) temperature: 350℃, capillary temperature: 320℃. By injecting the standard solution of a single analyte into the API source of the mass spectrometer, the parallel reaction monitoring (PRM) parameters of each target analyte were optimized, and the target compound standard solution was introduced into the mass spectrometer before UHPLC-MS / MS analysis. For each target compound, its PRM parameters were optimized; since most bile acid compounds did not have a strong enough daughter ion for quantification in the daughter ion spectrum, the parent ion under high resolution conditions was selected for quantification.
[0039] 1.6 Data Analysis
[0040] SPSS statistical software and R language were used to analyze the statistical processing results, and Origin 2024 and R language were used to generate the result graphs. One-way analysis of variance was used for data analysis, and statistical differences were considered when the P value was <0.05.
[0041] Results (The following experimental results are all tested after the 12-week intervention)
[0042] 2.1BG regulates weight gain in HFD-induced obese mice
[0043] After 12 weeks, the HFD group had a significant increase in body weight compared to the NOR group, and there was no significant difference in food intake between the two groups. In addition, the BG intervention resulted in a decrease in body weight gain compared to the HFD group, as shown in the Figure 1 .
[0044] 2.2BG improves liver dysfunction and lipid metabolism in HFD-induced obese mice
[0045] Plasma liver function biochemical indicators showed that HFD induced liver damage in mice, manifested by increased ALT and AST activities. In order to explore the potential effect of BG on HFD-induced liver damage, we evaluated liver function indicators. The data showed that compared with normal mice, the plasma AST, ALT, TG, TC and LDL-C levels in the HFD group were significantly increased, and the HDL-C level was significantly decreased. The results showed that BG treatment can improve HFD-induced liver damage and blood lipid levels. For specific results, see Figure 2 .
[0046] 2.3BG reduces liver fat accumulation in HFD-induced obese mice
[0047] Except for the NOR group, the livers of mice in the other groups showed varying degrees of fatty degeneration, accompanied by varying degrees of hepatocellular damage. In the NOR group, these changes were less obvious, and the presence of adipose tissue did not lead to hepatocellular damage. The results of the study showed that compared with the NOR group, the hepatic fat accumulation in the HFD group was significantly increased. Compared with the HFD group, the two BG intervention groups (BG-M group and BG-H group) showed improvements in HFD-induced hepatic fat accumulation and liver damage, among which the BG-H group had the most obvious effect. HE staining of colon tissue showed colon inflammatory cell infiltration in the HFD group, while no obvious inflammatory cell infiltration was found in the BG-M and BG-H groups. For specific results, see Figure 3 , Figure 4 .
[0048] 2.4BG restored HFD-induced changes in intestinal flora
[0049] Different diets lead to different gut microbiota compositions. To evaluate the effects of BG on gut microbiota, fecal samples of mice were collected for microbiological analysis. α-Diversity was calculated to determine the changes in microbial abundance and diversity among the five experimental groups. Microbial richness was assessed using Chao1 and abundance coverage-based Estimator (ACE), and microbial diversity was assessed using the Shannon and Simpson index. Although the abundance of gut microbiota in the HFD group was slightly increased compared with the NOR group, the results were not statistically significant. Principal component analysis (PCA) and principal coordinate analysis (PCoA) showed that there were substantial differences in microbiota composition between the NOR and HFD groups, and similar microbiota composition between the orlistat, BG-L, BG-M, and BG-H groups. To compare the microbial composition of cecal contents among the groups, microbial taxonomic analysis was performed at the phylum and genus levels. At the phylum level, Firmicutes, Bacteroidetes, Proteobacteria, and Epsilonbacteraetoa were dominant. Compared with the NOR group, the abundance of Firmicutes, Proteobacteria, and Epsilonbacteraetoa increased, and the abundance of Bacteroidetes decreased in the HFD group. Compared with the HFD group, the abundance of Firmicutes decreased, and the abundance of Bacteroidetes increased in the orlistat, BG-L, BG-M, and BG-H groups. Notably, an increase in the abundance ratio of Firmicutes / Bacteroidetes was positively correlated with obesity, and the abundance ratio was significantly reduced in the orlistat, BG-L, BG-M, and BG-H groups, suggesting that BG may treat obesity by affecting the intestinal microbiota. At the genus level, Helicobacter pylori, Lachnospiraceae NK4A136 group, Allobaculum, and Lactobacillus were the dominant genera in each group. Compared with the NOR group, the abundance of Helicobacteraceae NK4A136 group and Allobaculum was higher in the HFD group, while the abundance of Helicobacter pylori and Lactobacillus was lower. Compared with the HFD group, the abundance of Allobaculum was downregulated in the BG group, while the abundance of Helicobacter and Lactobacillus was upregulated.
[0050] In addition, nonparametric factorial Wilcoxon test, linear discriminant analysis (LEfSe) and linear discriminant analysis (LDA) were performed to explore specific biomarkers of intestinal microbiota. The results showed that there were significant differences in microbial abundance between HFD group mice and NOR group. LEfse analysis showed significant differences between the groups, with the highest abundance. For example, the NOR group was dominated by Bacteroidetes and Lactobacillales, including p-Bacteroidetes, c-Bacteroidiales, and o-bacteroidales. The species with significant differences and the highest abundance in the HFD group were mainly o-trichales, c-trichia, and f-tricaceae. The species with the highest abundance in the orlistat group were completely different from those in the HFD group, mainly composed of g-Faecalibaculum and g-Roseburia. There were significant differences in the species of different intestinal flora, including Spiraceae-NK4A136-group, g-A2 (BG-L group), such as f-Akkermansiaceae and g-Akkermansia (BG-M group), g-alloprevotella, and P-Proteobacteria (BG-H group). In summary, the structure of the intestinal flora changed significantly under the intervention of a high-fat diet. The ratio of Bacteroidetes and Firmicutes in mice in the HFD group was abnormal, resulting in a disordered intestinal flora structure. However, intervention with BG improved the intestinal microbiota of mice fed a HFD, indicating that BG can improve the damage to the intestinal flora caused by HFD. For specific results, see Figure 5-7 .
[0051] 2.5BG regulates abnormal bile acid metabolism in HFD-fed obese mice
[0052] Targeted metabolomics technology was used to analyze the bile acid composition of each group to explore the prevention of high-fat diet-induced metabolic syndrome by BG. The principal component analysis score plot showed that there were significant differences between the NOR group and the HFD group, and between the HFD group and the BG-H group. The heat map results showed that there were substantial differences in the composition of various bile acids between the NOR group and the HFD group, and between the HFD group and the BG-H group. We can more intuitively identify the bile acids that changed significantly in each group. Specifically, after a high-fat diet, the plasma concentrations of various bile acids increased, such as: hydrocholic acid (HCA), 6-ketolithocholic acid (6-ketolithocholic acid), isohydrodeoxycholic acid (isoDCA), dehydrocholic acid (DHLCA), polyoxycholic acid (MDCA), 3-dehydrocholic acid (3-DHCA), 7-ketolithocholic acid (7-ketolithocholic acid), hydrodeoxycholic acid (HDCA), and taurodeoxycholic acid (TCDCA). In contrast, the administration of BG led to different degrees of reduction in the levels of these bile acids. Specifically, compared with the HFD group, the levels of 7-ketoLCA and isoDCA in the BG-L group were significantly reduced, the level of 3-DHCA in the BG-M group was significantly reduced, and the levels of HCA, isoDCA, and 3-DHCA in the BG-H group were significantly reduced. Figure 8 .
[0053] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. Application of oat β-glucan in the preparation of fat-reducing products, characterized in that: The application is any of the following: (1) Reduce weight gain caused by a high-fat diet; (2) Improve liver damage and elevated blood lipid levels induced by a high-fat diet; (3) Reduce liver fat accumulation induced by a high-fat diet; (4) Improve intestinal flora disorders induced by high-fat diet; (5) Regulate abnormal bile acid metabolism caused by a high-fat diet.
2. The use according to claim 1, characterized in that: The oat beta-glucan is the only active ingredient in the fat-reducing product.
3. The use according to claim 2, characterized in that: The fat-reducing product is a health product.
4. The use according to claim 3, characterized in that: The dosage form of the fat-reducing product is tablets, powders, capsules, tea bags, water pills or oral liquids.
5. A fat-reducing product, characterized in that: The fat-reducing product contains oat beta-glucan.
6. The product according to claim 5, characterized in that The oat beta-glucan is the only active ingredient in the fat-reducing product.
7. The product according to claim 5 or 6, characterized in that The fat-reducing product is a health product.
Citation Information
Patent Citations
Food products with improved bile acid binding functionality and methods for their preparation
US20030147993A1
